(Q38019977)

27 August 2017

title

Emerging new agents for the management of patients with non-small cell lung cancer (English)

1 reference

27 August 2017

1 reference

Enrica Capelletto

1

1 reference

27 August 2017

Silvia Novello

series ordinal

2

1 reference

27 August 2017

publication date

1 June 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72 Suppl 1

1 reference

27 August 2017

page(s)

37-52

1 reference

Targeted therapies for non-small cell lung cancer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Current vaccine updates for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Ipilimumab: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Clinical implications of hedgehog signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F1163028-S0-000000000-00000

Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

1 reference

12 December 2020

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

1 reference

12 December 2020

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

12 December 2020

10.2165/1163028-S0-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1026964527

0 references

1 reference